Mithra CDMO Announces Collaboration with MedinCell for the Development of Injectable Products for Malaria and Transplant Rejection

- **Collaboration for the development of long-acting injectable innovative products to address major global healthcare challenges**
- **Two MedinCell's product candidates in the scope of the collaboration:**
  - **A 3-month long acting injectable designed as an additional tool to fight Malaria, one of the main health threats worldwide with more than 200 million people infected yearly**
  - **A long-acting injectable of tacrolimus for transplant patients aiming at improving efficacity, tolerance and patient observance**
- **Projects that perfectly combine Mithra CDMO's core activities: a broad experience in complex therapeutic polymeric forms and a specific know-how in flexible complex liquid injectables**

Liege, Belgium, 26 April 2022 – 7:30 CEST – Mithra (Euronext Brussels: MITRA) today announced a collaboration with MedinCell for the development of two long-acting injectable products in its CDMO based in Liège.

Mithra CDMO offers a complete spectrum of solutions from early drug development, clinical batches and commercial manufacturing of complex polymeric products (vaginal ring, implants) and complex liquid injectables and biologicals in vials, pre-filled syringes or cartridges.

Based in Montpellier (France), MedinCell develops a portfolio of long-acting injectable products in various therapeutic areas by combining its BEPO® technology with active ingredients already marketed. This technology makes it possible to control the regular delivery of a drug at the optimal therapeutic dose for a period of several days, weeks or months, by means of a simple depot injection. The depot is completely bioresorbable and is formed immediately after a subcutaneous or localised injection. As real alternative to conventional methods of taking medicines, MedinCell's technology offers a number of advantages to address major healthcare challenges around the world, potentially improving efficacity, tolerance and patient observance, as well as rapid development.

1. Treatment for Malaria supported by global health agency Unitaid

MedinCell's product candidate "mdc-STM" is a 3-month ivermectin formulation aiming to reduce the transmission of the parasite responsible for Malaria, thanks to a killing effect on the vector mosquitoes when they bite treated people. Administered at the beginning of the transmission season, this long-acting injectable product could have a significant epidemiological impact. Malaria remains pandemic in 91 countries representing 50% of the world's population. According to WHO estimates, 228 million people were infected worldwide in 2018, 93% of them in Africa, leading to 405,000 deaths. Children under 5 years are the most vulnerable, accounting for 67% of deaths from malaria.

This R&D Program is financially supported by the global health agency Unitaid[1]. Regulatory preclinical activities has started in 2020 with the objective of a first clinical trial in 2023 supported by Mithra CDMO.

2. Treatment to prevent transplant rejection

MedinCell's product candidate "mdc-GRT" is a sub-cutaneous treatment based on immunosuppressant tacrolimus to prevent graft rejection in organ transplant patients. In addition to improve compliance, a major issue in patients who have received a transplant associated with a necessary lifelong treatment, this product could reduce the risk of adverse effects. Mithra CDMO will take care of the development of this product for preclinical and clinical trials in 2023.

Renaat Baes, CDMO Site Director, Mithra CDMO, commented: *"We are very pleased to collaborate with MedinCell on complex technology products that perfectly match our combined expertise in polymers and injectables. These technologies based on an extended and controlled release of the drug provide many advantages to patients and offer both effective and affordable alternatives for treating chronic or pandemic diseases, such as malaria. Our Mithra CDMO provides quite specific know-how covering a complete range of services in development and production of these high value-added products and intends to further strengthen its activities in these growing markets."*

****

For more information, please contact:

Mithra CDMO
Benoît Mathieu (IRO) : +32 473 35 80 18- investorrelations@mithra.com
Maud Vanderthommen (Presse) : +32 473 58 61 04 – press@mithra.com

About Mithra

Mithra (Euronext: MITRA) is a Belgian biotech company dedicated to transforming Women's Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Mithra explores the potential of the unique native estrogen estetrol in a wide range of applications in women health and beyond. After having successfully launched the first estetrol-based product in 2021, the contraceptive pill Estelle®, Mithra is now focusing on its second product Donesta®, the next-generation hormone therapy. Mithra also develops and manufactures complex therapeutics in the areas of contraception, menopause and hormone-dependent cancers. It offers partners a complete spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO. Active in more than 100 countries around the world, Mithra has an approximate headcount of 300 staff members and is headquartered in Liège, Belgium. www.mithra.com

Important information

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology,

[1] Press release MedinCell, 14/06/2021

including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.